Everyone knows CBD is FDA-approved for seizures, and almost everyone misreads what that means. It is purified pharmaceutical CBD, in three rare syndromes, and it says nothing about a strain's terpene profile.
What patients are managing
Epilepsy and intractable seizures are qualifying conditions in Pennsylvania. This is the condition where the gap between a true headline and a safe conclusion is widest, so precision here is not pedantry. It is the difference between an evidence-based expectation and a dangerous one.
What the research supports: cannabinoids
The headline is real. The FDA approved Epidiolex, a purified plant-derived CBD solution, in 2018 for Lennox-Gastaut and Dravet syndromes and in 2020 for tuberous sclerosis complex, backed by pivotal randomized trials, including one in Dravet syndrome where CBD cut convulsive seizure frequency against placebo. That is genuine grade-A evidence. It is also specific in every direction: purified pharmaceutical CBD, at controlled doses, in three rare syndromes, not THC and not a dispensary strain.
Worth knowing before you buyThe approved evidence is for a purified CBD medicine, not for choosing a cannabis strain by its terpenes, and no terpene has human seizure evidence at all. High-THC products carry their own risks, and cannabinoid seizure medicine can interact with other drugs. If you have epilepsy, a strain choice made on a terpene panel has no human evidence behind it, and nothing here should be used to substitute for your anti-seizure medication.
What the research supports: terpenes
The terpene evidence is preclinical. Beta-caryophyllene protected against seizures in mouse models, in one test comparably to phenytoin, and reduced seizure scores in chemically induced status epilepticus alongside lower oxidative stress. Linalool has anticonvulsant activity in animal seizure models. Both are mouse and rat data. No human terpene seizure study exists.
What the research does not support
There is no human evidence that any terpene reduces seizures, and the famous CBD approval is for a purified drug in specific rare syndromes, not for a strain's terpene profile. This is the most dangerous condition on which to blur cannabinoid evidence into a terpene claim, so Terpenology will not show a terpene-driven score that implies seizure control. Choosing a product on terpenes for epilepsy means relying on animal data, and you deserve to know that plainly.
How Terpenology scores this
Terpenology treats epilepsy as a very-low-confidence, hard-caveat condition. It states that the approved evidence is purified pharmaceutical CBD, not terpenes, and that terpene seizure evidence is animal-only. The app will not present a terpene panel as if it predicts seizure control, and it pairs any mention with the clear message not to substitute for prescribed anti-seizure treatment.
Terpenes worth reading about
Terpenology is educational, not medical advice. Terpene effects are tendencies commonly reported by patients and early research, never guaranteed outcomes. Nothing here is a substitute for the care of your certifying physician, your pharmacist, or the specialist treating your condition.